Abstracts tagged "Biomarkers"

Abstract Number: 1454 • 2018 ACR/ARHP Annual Meeting
Levels of 14-3-3eta Are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis
Gilles Boire¹, Nathalie Carrier², Artur J deBrum Fernandes³, Patrick Liang¹, Ariel Masetto⁴, Sophie Roux⁴, Norma K Biln⁵, Yuan Gui⁵, Jane Savill⁵, Sara Michienzi⁵ and Walter P. Maksymowych⁶, ¹Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ³Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Augurex Life Sciences Corp, Vancouver, BC, Canada, ⁶Department of Medicine, CaRE Arthritis and University of Alberta, Edmonton, Canada, Edmonton, AB, Canada
Background/Purpose: Our objective is to examine the additional contribution of 14-3-3η levels to known predictors of radiographic progression in inflammatory polyarthritis, both over several years…
Abstract Number: 1998 • 2018 ACR/ARHP Annual Meeting
Autophagy-Related Molecules Detected in Blood and Cartilage Are Biomarkers of Joint Damage in OA
Beatriz Carames¹, Irene Lorenzo Gomez¹, Jose Antonio Pinto Tasende², Natividad Oreiro Villar² and Francisco J Blanco¹, ¹Cartilage Biology Group, Rheumatology Division, INIBIC-CHUAC, A Coruña, A Coruña, Spain, ²Clinical Rheumatology Division, Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, A Coruña, Spain
Background/Purpose: In osteoarthritis (OA), defects in cellular homeostasis, and in particular in autophagy, are evident and precede joint damage. We have shown that there is…
Abstract Number: 2816 • 2018 ACR/ARHP Annual Meeting
Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Joseph F. Solus¹, Quanhu Sheng¹, Fei Ye¹, Yan Guo¹, Qiong Wu¹, Annette M. Oeser¹, Ryan Allen¹, Paolo Raggi², Kasey Vickers¹ and C Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), regulate gene expression and can be used as biomarkers of disease. Patients with rheumatoid arthritis (RA)…
Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting
Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE
Anne C. Bay-Jensen¹, Christian S. Thudium¹, Claus Christiansen² and Morten A. Karsdal¹, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
Abstract Number: 1064 • 2018 ACR/ARHP Annual Meeting
Identification of a Panel of Circulating Proteins Associated to Synovial Pathotypes in Early Rheumatoid Arthritis Patients
Cristina Ruiz-Romero¹, Florencia Picchi², Patricia Fernández³, Lucia González², Rebecca Hands⁴, Valentina Calamia², Maria Camacho², Conrad Bessant⁵, Costantino Pitzalis⁴ and Francisco J Blanco⁶, ¹Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁵School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, ⁶Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is characterized by high clinical variability and an underlying cellular and molecular heterogeneity. Efforts to find tools for the classification of…
Abstract Number: 1456 • 2018 ACR/ARHP Annual Meeting
Neutrophil Activation Is Associated with Disease Activity and Predicts Development of Erosive Disease and Extra Articular Manifestations in Rheumatoid Arthritis
Mary Bach^1,2, Tiffany Pan³, J. Lee Nelson^3,4 and Christian Lood⁵, ¹VA Puget Sound Health Care System, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Fred Hutchinson Cancer Research Center, Seattle, WA, ⁴Division of Rheumatology, University of Washington, SEATTLE, WA, ⁵Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation is associated with inflammation and autoimmunity, including rheumatoid arthritis (RA), where neutrophil infiltration into joints participates in tissue destruction and development of…
Abstract Number: 2002 • 2018 ACR/ARHP Annual Meeting
Dynamic Compression of Articular Cartilage Explants Increases Formation and Decreases Degradation of Type II Collagen
Amalie Engstrøm^1,2, Anne C. Bay-Jensen², Morten A. Karsdal² and Christian S. Thudium², ¹Department of Biomedical Science, University of Copenhagen, København, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Mechanical loading is recognized as a major factor in initiation and progression of osteoarthritis (OA). Conversely loading is believed to play an essential role…
Abstract Number: 2821 • 2018 ACR/ARHP Annual Meeting
Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
Cecilie Heegaard Brahe¹, Simon Krabbe¹, Mikkel Østergaard¹, Lykke Midtbøll Ørnbjerg¹, Daniel Glinatsi¹, Henrik Rogind¹, Hanne Slott Jensen², Annette Hansen³, Jesper Nørregaard⁴, Søren Jacobsen⁵, Lene Terslev¹, Tuan Khai Huynh⁴, Dorte Vendelbo Jensen⁶, Natalia Manilo², Karsten Asmussen², Per Brown-Frandsen⁵, Mikael Boesen⁷, Zoreh Rastiemadabadi⁷, Lone Morsel-Carlsen⁷, Jakob M. Møller⁸, Niels Steen Krogh⁹ and Merete Lund Hetland¹⁰, ¹Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ²Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Nordsjællands Hospital, Hillerød, Denmark, Hillerød, Denmark, ⁵Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Copenhagen, Denmark, ⁷Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ⁸Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, ¹⁰DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors Background/Purpose: A cohort of routine care…
Abstract Number: 618 • 2018 ACR/ARHP Annual Meeting
Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis
Cristina Sobrino¹, Borja Hernández-Breijo², Israel Gañán-Nieto¹, Carlota García-Hoz¹, Victoria Navarro-Compán², Ana Martínez², Javier Bachiller¹, María Gema Bonilla Hernán², Dora Pascual-Salcedo², Garbiñe Roy¹, Mónica Vázquez¹, Alejandro Balsa², Luisa María Villar¹, Chamaida Plasencia² and Eulalia Rodríguez-Martín¹, ¹Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFi) are the most common biologicalagents used as disease-modifying treatment in rheumatoid arthritis (RA). Although these drugs have contributed to change the…
Abstract Number: 1077 • 2018 ACR/ARHP Annual Meeting
Identification of Biomarkers Involved in the Resolution Phase of Inflammation: Specialized Pro-Resolving Mediator Receptors Expression in Rheumatoid Arthritis
Simone Perniola¹, Liliana Dinoia¹, Nunzia Lacarpia¹, Dorotea Natuzzi¹, Rita Bizzoca¹ and Florenzo Iannone², ¹Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ²D.E.T.O., Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy
Background/Purpose: Inflammation is part of the complex biological response of body tissues to harmful stimuli, involving immune cells, blood vessels, and molecular mediators. At the…
Abstract Number: 1467 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics
Lucía González-Rodríguez¹, Valentina Calamia¹, Patricia Fernández², Cristina Ruiz-Romero³, Antonio Julià⁴, Antonio Fernández-Nebro⁵, Jesús Tornero⁶, Sara Marsal⁴ and Francisco J Blanco³, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ³Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Spain, ⁵UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Spain, ⁶Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 2008 • 2018 ACR/ARHP Annual Meeting
Vascular Adhesion Protein-1 (VAP-1) As Predictor of Radiographic Severity in Symptomatic Knee Osteoarthritis
Eirini Bournazou¹, Jonathan Samuels², Hua Zhou³, Svetlana Krasnokutsky Samuels⁴, Jyoti Patel⁵, Jenny Bencardino⁶, Leon Rybak⁷, Steven Abamson⁸, Uwe Junker⁹, Karen Brown¹ and Mukundan Attur⁵, ¹Roche Innovation Center, New York, NY, ²Department of Medicine, Divison of Rheumatology, NYU Langone Health, New York, NY, ³Bioinformatics, New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Rheumatology Research, NYU Langone Orthopedic Hospital, New York, NY, ⁶Radiology, NYU Langone Medical Center, New York, NY, ⁷Department of Radiology, NYU Langone Medical Center, New York, NY, ⁸Rheumatology, NYU Langone Health, New York, NY, ⁹Roche Innovation Center, Basel, Switzerland
Background/Purpose: To investigate the expression of vascular adhesion protein -1 (VAP-1) in joint tissues and serum in knee osteoarthritis (OA) patients and examine whether VAP-1…
Abstract Number: 2833 • 2018 ACR/ARHP Annual Meeting
Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Rosalind Ramsey-Goldman¹, Roberta Alexander², Elena Massarotti³, Daniel J. Wallace⁴, Sonali Narain⁵, Cristina Arriens⁶, Christopher E. Collins⁷, Amit Saxena⁸, Chaim Putterman⁹, Kenneth C. Kalunian¹⁰, Armida Sace², Rowena Lafon², Tyler O'Malley², JoAnne Ligayon², Claudia Ibarra², John Conklin², Thierry Dervieux² and Arthur Weinstein⁷, ¹FSM, Northwestern University, Chicago, IL, ²Exagen Diagnostics, Inc., Vista, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Northwell Health, Great Neck, NY, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ⁸NYU Langone Health, New York, NY, ⁹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹⁰Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: We showed previously that complement activation - cell-bound complement activation products (CB-CAPS) or multi-analyte assay panel (MAP) - is a sensitive and specific biomarker…
Abstract Number: 713 • 2018 ACR/ARHP Annual Meeting
Soluble ST2 and CXCL-10 May Serve As Biomarkers of Diastolic Dysfunction in SLE and Correlate with Disease Activity and Damage
Udi Chorin¹, Aviram Hochstadt¹, David Levartovsky², Irena Litinsky³, Ofir Elalouf⁴, Ari Polachek⁵, Ilana Kaufman⁶, Uri Arad⁷, Valerie Aloush⁷, Sara Borok Lev-Ran⁸, Irena Wigler⁷, Jonathan Wollman⁷, Dan Caspi², Yael Lahat², Or Carmi², Shlomo Berliner⁹, Ori Elkayam⁷, Yan Topilsky¹ and Daphna Paran², ¹Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv Univrsity, Tel Aviv, Israel, ⁶Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁷Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ⁸Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel AViv, Israel, ⁹Internal Medicine E, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Background/Purpose: Subclinical myocardial dysfunction has been reported to occur earlyin SLE. The pathogenesis and prognosis of this finding is not clear. The study aims to…
Abstract Number: 1081 • 2018 ACR/ARHP Annual Meeting
Associations between Daily Alcohol Intake and SLE-Related Cytokines and Chemokines U.S. Female Nurses without SLE
Cianna Leatherwood¹, Xinyi Liu¹, Susan Malspeis², Andrea Roberts³, Jeffrey A. Sparks¹, Elizabeth Karlson¹, Candace H. Feldman¹, Judith A. James⁴, Laura Kubzansky⁵ and Karen Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴OMRF & OUHSC, Oklahoma City, OK, ⁵Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Low or no alcohol intake (0-5 gm/day or <0.5 drinks/day) has been associated with increased SLE risk among women. Several cytokines and chemokines are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].